检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:张永成[1] 向海卿[1] 杨焰[2] 严冬梅[2] 梁超[3]
机构地区:[1]广东药学院附属第一医院乳腺科,广东广州510080 [2]广东药学院附属第一医院B超室,广东广州510080 [3]第二军医大学临床医学系,上海200433
出 处:《中国肿瘤外科杂志》2010年第2期90-92,共3页Chinese Journal of Surgical Oncology
摘 要:目的探讨B超引导下分别使用VACORA(万可)和Mammotome(麦默通)系统对乳腺良性肿物进行微创旋切术的临床应用比较。方法在B超引导下,分别使用VACORA和Mammotome系统对48例123个乳腺肿物进行微创旋切,记录手术时间和术后情况并进行对比。结果 48例123处乳腺肿物经微创旋切术后获得明确病理诊断,平均手术时间VACORA组为55.31 min,Mammotome组为25.22 min,二组相比差异有统计学意义(P<0.05)。术后发生局部血肿2例(2.7%),皮下淤斑5例(6.7%),无术后感染。术后随访3-12个月,无肿物复发。结论使用VACORA和Mammotome系统治疗乳腺良性肿瘤具有定位准确、创伤小、出血少、易操作、并发症少以及术后外形美观等优点。前者体积小,重量轻,便于携带;后者手术时间短,操作更加简便。Objective: To evaluate the clinical application of ultrasound guided VACORA and Mammotome for the treatment of breast benign tumors and to compare the clinical value of the two minimally invasive biopsy systems. Methods: Under the direction of ultrasound, 123 benign breast tumors of 48 women were completely excised by using Mammotome or VACORA. The intraoperative and postoperative data were recorded and compared. Results: 123 breast tumors of 48 women were all diagnosed by pathology, the mean operate time of VACORA and Mammotome groups were 55.31 and 25.22 minutes respectively, The difference was significant. The difference of mean incision times was not significant. The postoperative follow time was 3~12 months. There were 2 cases(2.7%) of local hematoma, 5 cases(6.7%) of subcutaneously hematoma, no recurrence and infection. Conclusion: There are many advantages using ultrasound-guided minimally invasive technique for the treatment of benign breast disease, including accurate localization, minimal invasion, less blood, easy operation, few complications and good cosmetology. The former is smaller, lighter and can be easily carried, while the latter can make operative time shorter and operation easier.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145